Introduction
============

Diabetic nephropathy is the most common cause of end-stage renal disease in the world, and could account for disability and high mortality rate in patients with diabetes. According to the World Health Organization, it is expected that the number of patients with diabetes will rise to 370 million by 2030 in the world.[@R1] It has also been reported that about 25--40% of type 1 or type 2 diabetic patients develop diabetic nephropathy within 20--25 year of the onset of diabetes.[@R2] Large clinical trials such as United Kingdom Prospective Diabetes Study (UKPDS) and Diabetes Control and Complications Trial (DCCT) revealed that strict control of blood glucose or blood pressure significantly reduced the development and progression of diabetic nephropathy in both type 1 and type 2 diabetes.[@R3],[@R4] However, current therapeutic options are far from satisfactory, and the effects of intensive therapy on diabetic nephropathy are insufficient. Indeed, intensive therapy of blood glucose and/or blood pressure is often difficult to maintain and may increase the risk of hypoglycemia and/or hypotension in diabetic patients, and number of diabetic patients with end-stage renal failure is still increasing in industrialized countries. Therefore, development of novel therapeutic strategies that could specially target diabetic nephropathy is urgently needed.

Various hyperglycemia-induced metabolic and hemodynamic derangements, including increased formation of advanced glycation end products (AGEs), enhanced reactive oxygen species (ROS) generation and activation of protein kinase C (PKC), polyol pathway and renin-angiotensin system (RAS), are considered to contribute to the development and progression of diabetic nephropathy.[@R5] However, a follow-up study of DCCT called DCCT-Epidemiology of Diabetes Interventions and Complications (DCCT-EDIC) study, has shown that the reduction in the risk of progressive retinopathy and nephropathy resulting from intensive therapy in patients with type 1 diabetes persisted for at least several years, despite increasing hyperglycemia.[@R6],[@R7] Intensive therapy during the DCCT resulted in decreased progression of intimamedia thickness and subsequently reduced the risk of nonfatal myocardial infarction, stroke, or death from cardiovascular disease by 57 percent 11 years after the end of the trials.[@R8],[@R9] Further, a recent follow-up study of UKPDS called UKPDS80 also has shown that benefits of an intensive therapy in patients with type 2 diabetes are sustained after the cessation of the trial.[@R10] In this study, despite an early loss of glycemic differences between intensive and conventional therapy, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up.[@R10] These observations indicate that intensive therapy to control blood glucose has long-term beneficial effects (legacy effects) on the risk of diabetic retinopathy, nephropathy, cardiovascular disease (CVD) and death in patients with both type 1 and type 2 diabetes, strongly suggesting that so-called 'metabolic memory' could cause chronic damage in diabetic vessels that are not easily reversed, even by subsequent, relatively good control of blood glucose.

Reducing sugars can react non-enzymatically with the amino groups of proteins to form reversible Schiff bases, and then Amadori products.[@R5],[@R11]--[@R14] These early glycation products undergo further complex reactions such as rearrangement, dehydration and condensation to become irreversibly cross-linked, heterogeneous fluorescent derivatives termed AGEs.[@R5],[@R11]--[@R14] The formation and accumulation of AGEs have been reported to progress at an accelerated rate under diabetes. The pathological role of the nonenzymatic glycation of proteins has become increasingly evident in various disorders including diabetic vascular complications.[@R5],[@R15]--[@R19] Furthermore, there is a growing body of evidence that AGEs and their signal-transducing receptor interaction evokes oxidative stress and subsequently elicits vascular inflammation and thrombosis, thereby playing a central role in the pathogenesis of vascular complications in diabetes.[@R5],[@R20]--[@R24]

Although the exact pathophysiological mechanisms responsible for a legacy effect of the intensive glycemic control or metabolic memory are unclear, biochemical nature of AGEs, that is, gradual accumulation of AGEs under hyperglycemic conditions that are subsequently slowly degraded with intensive glycemic control, is compatible with the concept 'metabolic memory'.[@R5],[@R11]--[@R14] Further, AGEs and/or diabetic conditions are shown to upregulate receptor for AGEs (RAGE) expression in various cell types and induce sustained activation of transcriptional factor nuclear factor-κB (NFκB).[@R5],[@R25]--[@R27] Therefore, it is conceivable that the AGE-RAGE-induced oxidative stress generation further potentiates the formation and accumulation of AGEs under diabetic conditions, [@R28] and these positive feedback loops between AGEs and RAGE-downstream pathways could make a vicious cycle, thus providing a mechanistic basis for understanding the concept of 'metabolic memory' in vascular complications in diabetes. Since the above-mentioned observations suggest that the AGE-RAGE-induced ROS generation is a novel molecular target for vascular complications in diabetes, we review here the pathophysiological role of AGE-RAGE-oxidative stress system and its therapeutic interventions in diabetic nephropathy.

Role of AGEs in Diabetic Nephropathy
====================================

In type 1 and type 2 diabetic patients, serum and tissue AGEs levels were significantly increased compared with non-diabetic control subjects.[@R29],[@R30] Further, diabetic patients with end-stage renal disease had almost twice as much AGEs in tissue as diabetic patients without renal disease.[@R29] Both enhanced formation and decreased clearance are responsible for the accumulation of AGEs in patients with diabetic nephropathy.[@R31],[@R32] Indeed, serum levels of low molecular weight-AGEs, which are degradated products of tissue AGEs by macrophages, are reported to increase in diabetic and non-diabetic subjects with renal dysfunction.[@R33]--[@R35] Since low molecular weight-AGEs are filtered by the kidney and then reabsorbed by proximal tubular cells,[@R36] decreased glomerular filtration rate and tubulointerstitial cell damage could also be involved in AGEs accumulation in patients with diabetic nephropathy. Further, we have previously found that non-*N*^e^-(carboxymethyl)lysine (CML) AGEs are increased in parallel to the severity of diabetic nephropathy in type 1 diabetic patients.[@R37] AGEs-modified collage levels in the skin are reported to be one of the predictors for diabetic nephropathy and correlated with the severity of nephropathy in patients with long-standing type 1 diabetes as well.[@R31],[@R32]

Accumulation of AGEs in the kidney may contribute to the progressive alteration in renal architecture and loss of renal function in patients and rodents via various mechanisms, including their cross-linking (β-sheets or cross-β structure) properties of matrix proteins and activation of the downstream signalings.[@R38]--[@R41] AGE formation on extracellular matrix proteins alters both matrix-matrix and cell-matrix interactions, being involved in diabetic glomerulosclerosis. For example, non-enzymatic glycations of type IV collagen and laminin reduce their ability to interact with negatively charged proteoglycans, increasing vascular permeability to albumin.[@R42] Further, AGE formation on various types of matrix proteins impairs their degradation by matrix metalloproteinases, contributing to basement membrane thickening and mesangial expansion, hallmarks of diabetic nephropathy.[@R43],[@R44] AGEs formed on the matrix components can trap and covalently cross-link with the extravasated plasma proteins such as lipoproteins, thereby exacerbating diabetic glomerulosclerosis.[@R44] AGEs including glycoxidation or lipoxidation products such as CML, pentosidine, malondialdehyde-lysine accumulate in the expanded mesangial matrix and thickened glomerular basement membranes of early diabetic nephropathy, and in nodular lesions of advanced disease, further suggesting the active role of AGEs for diabetic nephropathy.[@R45]

AGEs induce apoptotic cell death and vscular endothelial growth factor (VEGF) expression in human cultured mesangial cells, as the case in pericytes, a counterpart of mesangial cells in retinas.[@R46] Mesangial cells occupy a central anatomical position in the glomerulus, playing crucial roles in maintaining structure and function of glomerular capillary tufts.[@R47] They actually provide structural support for capillary loops and modulate glomerular filtration by its smooth muscle activity.[@R47]--[@R49] Therefore, the AGE-induced mesangial apoptosis and dysfuction may contribute in part to glomerular hyperfiltration, an early renal dysfunction in diabetes. Recently, antibodies against VEGF have been found to improve hyperfiltration and albuminuria in experimental diabetes, supproting our speculation.[@R50] Further, we have recently found that AGEs stimulate monocyte chemoattractant protein-1 (MCP-1) expression in mesangial cells.[@R46] Increased MCP-1 expression associated with monocyte infiltration in mesangium has been observed in the early phase of diabetic nephropathy.[@R51] Urinary MCP-1/creatinine ratios in type 2 diabetic patients with microalbuminuria were much higher than those in normal controls, and intensive insulin treatment decreased significantly the urinary MCP-1/creatinine ratios.[@R52] Therefore, AGE accumulation in glomerulus could also be implicated in the initiation of diabetic nephropathy by promoting the secretion of MCP-1 in mesangial cells.

AGEs stimulate insulin-like growth factor-I, -II, platelet-derived growth factor and transforming growth factor-β (TGFβ) in mesangial cells, which in turn mediate production of type IV collagen, laminin and fibronectin.[@R53],[@R54] AGEs induce TGFβ overexpression in both podocytes and proximal tubular cells as well.[@R55],[@R56] Recently, Ziyadeh et al. reported that long-term treatment of type 2 diabetic model mice with blocking antibodies against TGFβ suppressed excess matrix gene expression, glomerulosclerosis, and prevented the development of renal insufficiency.[@R57] These observations suggest that AGE-induced TGFβ expression plays an important role in the pathogenesis of glomerulosclerosis and tubulointerstitial fibrosis in diabetic nephropathy.[@R58],[@R59]

In vivo, administration of AGE-albumin to normal healthy mice for 4 weeks has been found to induce glomerular hypertrophy with overexpression of type IV collagen, laminin B1 and TGFβ genes.[@R60] Furthermore, chronic infusion of AGE-albumin to otherwise healthy rats leads to focal glomerulosclerosis, mesangial expansion, and albuminuria.[@R61]

Role of RAGE and Oxidative Stress in Diabetic Nephropathy
=========================================================

There is accumulating evidence that AGE-RAGE axis is involved in the pathogenesis of diabetic nephropathy.[@R55],[@R62]--[@R64] Among various types of AGE receptors, RAGE is a signal transducing receptor for AGEs that could mediate the inflammatory reactions evoked by AGEs.[@R5],[@R20]--[@R24] In humans, RAGE expression is enhanced in podocytes and mesangial cells in diabetic patients with nephropathy.[@R62],[@R63] Several animal studies have also supported the crucial role for RAGE in the development and progression of diabetic nephropathy. Indeed, RAGE-overexpressing diabetic mice have been found to show progressive glomerulosclerosis with renal dysfunction, compared with diabetic littermates lacking the RAGE transgene.[@R64] Further, Wendt et al. reported that diabetic homozygous RAGE null mice failed to develop mesangial matrix expansion or thickening of the glomerular basement membrane.[@R55] They also claimed in their report that activation of RAGE in podocytes could contribute to expression of VEGF and enhanced attraction/activation of inflammatory cells in the diabetic glomeruli, causing albuminuria and glomerulosclerosis in diabetes.[@R55] In addition, it has been reported that *db/db* or streptozotocin-induced diabetic mice develop renal changes seen in human diabetic nephropathy such as glomerular hypertrophy, glomerular basement membrane thickening, mesangial matrix expansion, connective tissue growth factor (CTGF) overexpression, and NFκB activation, all of which are blocked by the administration of neutralizing antibody raised against RAGE.[@R65],[@R66] The AGE-RAGE interaction can also induce sustained activation of NFκB as a result of increased levels of de novo synthesized NFκBp65 overriding endogenous negative feedback mechanisms and thus might contribute to the persistent damage to diabetic kidney.[@R27]

Engagement of RAGE with AGEs elicits oxidative stress generation, thus participating in diabetic nephropathy ([**Table 1**](#T1){ref-type="table"}).[@R5],[@R20]--[@R24] Indeed, ROS are cytotoxic to renal cells and promote inflammatory and fibrogenic reactions in diabetic kidney.[@R46],[@R56],[@R67]--[@R69] The AGE-RAGE-mediated ROS generation stimulates production of pro-sclerotic growth factors such as TGFβ and CTGF via mitogen-activated protein kinase (MAPK), NFκB and/or PKC pathways in both mesangial and renal tubulointerstitial cells.[@R46],[@R56],[@R67]--[@R69] Moreover, Tallas-Bonke et al. have recently reported that inhibition of NADPH oxidase by apocynin prevents the AGE-elicited renal damage in experimental diabetic nephropathy through a PKC-α dependent pathway.[@R70] Therefore, the inhibition of NADPH oxidase-derived ROS generation elicited by AGE-RAGE system may be a novel therapeutic target for the treatment of diabetic patients with nephropathy.

TGFβ is a well-known pro-fibrogenic factor.[@R71] It not only stimulates matrix synthesis, but also inhibits matrix degradation, being involved in tubuloglomerular sclerosis in diabetes.[@R71] TGFβ mRNA and protein levels are significantly increased in glimeruli and tubulointerstitium in type 1 and 2 diabetic animals and patients.[@R69],[@R72],[@R73] AGE accumulation in diabetic kidney is shown to be closely linked to renal expression of TGFβ[@R55]--[@R57],[@R72],[@R73] and administration of AGEs was reported to increase renal TGFβ levels in conjunction with increase in AGEs accumulation in diabetic rodents.[@R74] In addition, we have previously found that AGEs activate TGFβ-Smad system though the interaction with RAGE in cultured mesangial cells.[@R75] Moreover, Oldfield et al. have reported that AGEs cause TGFβ-induced epithelial-tomesenchymal transdifferentiation via interaction with RAGE in normal rat kidney epithelial cell line, NRK 52E cells as well.[@R76] These observations suggest the pathological role for the AGE-RAGE axis in glomerular sclerosis and tubulointerstitial fibrosis, which is a molecular target for prevention of diabetic nephropathy ([**Fig. 1**](#F1){ref-type="fig"}). In support of this speculation, inhibition of AGE formation by pylidoxamine was shown to reduce renal TGFβ mRNA levels in association with decrease in urinary albumin excretion rate in KK-A(y)/Ta mice, an animal model of type 2 diabetes.[@R77] An AGEs-crosslink breaker, ALT-711, or OPB-9195, an inhibitor of AGE formation was reported to ameliorate renal injury in diabetic animals by suppressing TGFβ overexpression in diabetic animals as well.[@R78],[@R79]

CTGF has been considered to act as a downstream target of TGFβ in diabetic nephropathy.[@R80] Several papers have suggested an active role for CTGF in diabetic nephropathy.[@R80]--[@R82] CTGF levels in the glomeruli are increased in diabetic animals, and plasma levels of CTGF are reported to be elevated in patients with diabetic nephropathy.[@R81],[@R82] Further, Twigg et al. have recently found that an inhibitor of AGEs, aminoguanidine decreases renal CTGF and fibronectin levels in experimental diabetic nephropathy.[@R82] They also showed that ALT-711 reduced renal CTGF levels in their models.[@R82] Since CTGF also plays a role in the AGE-induced epithelial-to-mesenchymal transdifferentiation,[@R83] suppression of CTGF expression may be a potential therapeutic target for tubuloglomerulosclerosis in diabetic nephropathy.

Therapeutic Interventions of the AGE-RAGE-Oxidative Stress System in Diabetic Nephropathy
=========================================================================================

Several large clinical studies have reported the potential utility of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin II (Ang II) type 1 receptor blockers (ARBs) for the treatment of hypertensive diabetic patients with microalbuminuria or overt nephropathy ([**Table 2**](#T2){ref-type="table"}).[@R84]--[@R88] Although blood pressure-lowering property could largely explain the beneficial effects of these agents on diabetic nephropathy, there is accumulating evidence to suggest that ACE-Is or ARBs may exert salutary effects on diabetic nephropathy, at least in part, by blocking the pathological crosstalk between the RAS and the metabolic pathways such as AGE-RAGE axis.[@R89] Indeed, angiotensinogen production by cultured proximal tubular cells is increased in response to high glucose concentration, and the intrarenal Ang II level is significantly higher than that in serum in patients with diabetic nephropathy.[@R90],[@R91] Further, high glucose stimulates Ang II generation in association with increased TGFβ1 production by cultured mesangial cells.[@R92]

Since Ang II increases intracellular ROS generation in renal cells, it may stimulate the production of AGEs and further augment the AGE-RAGE system in diabetic kidney.[@R93]--[@R98] There is accumulating in vitro- and in vivo-evidence to suggest the pathophysiological crosstalk between the RAS and AGE-RAGE axis in diabetic nephropathy. Indeed, we have previously found that AGEs activate mesangial TGFβ-Smad system through the autocrine production of Ang II via oxidative stress generation.[@R75] Miyata et al. have recently reported that an ACE-I temocapril and an ARB olmesartan significantly inhibit in vitro-formation of pentosidine and CML.[@R95] In animal models, Forbes et al. have reported that ACE-I decreases circulating and renal tissue levels of AGEs in experimental diabetic nephropathy.[@R93] An ARB reduced renal levels of AGEs in AGE-injected animals as well, while Ang II infusion accelerated the formation and accumulation of AGEs in both glomeruli and renal tubules in their models.[@R94] In addition, administration of olmesartan medoxomil was found to inhibit the increase of systolic and diastolic blood pressure levels and urinary N-acetyl-beta-D-glucosaminidase activity and prevent glomerulosclerosis in exogenously AGE-injected rats.[@R96] In humans, an ACE-I, ramipril treatment has been shown to result in a mild decline of fluorescent non-CML-AGE and malondialdehyde concentrations in non-diabetic nephropathy patients.[@R97] In type 2 diabetic subjects, a low-dose of valsartan treatment was reported to decrease serum AGE levels in a blood pressureindependent manner.[@R98] These observations suggest that beneficial effects of the blockade of the RAS on diabetic nephropathy could be ascribed at least in part to its inhibitory effects of the AGE-RAGE-oxidative stress system.

Several papers have shown that peroxisome proliferatoractivated receptor-γ (PPARγ) agonists block the deleterious effects of AGEs and exert beneficial actions on diabetic nephropathy.[@R99]--[@R110] Indeed, activation of PPARγ by rosiglitazone inhibited AGE-induced inducible nitric oxide (NO) synthase expression, nitrite release, fibronectin and type IV collagen production by mesangial cells.[@R99],[@R100] Rosiglitazone attenuated the AGE-induced interleukin-8 and soluble intercellular adhesion molecule-1 (ICAM-1) generation by proximal tubular epithelial cells as well through the suppression of signal transducer and activator of transcription (STAT).[@R101] Further, rosiglitazone was reported to inhibit renal extracellular matrix accumulation, fibronectin, type IV collagen and plasminogen activator inhibitor-1 (PAI-1) production and subsequently reduce proteinuria in AGE-injected rats.[@R101]

Suppression of RAGE expression may be a molecular target of PPARγ agonists.[@R102]--[@R111] Marx et al. reported that stimulation of human endothelial cells with PPARγ agonists such as rosiglitazone and pioglitazone decreased basal as well as tumor necrosis factor-alpha-induced RAGE expression via suppression of NFκB activation. They also showed that PPARγ agonists decreased AGE-induced MCP-1 expression in endothelial cells.[@R102] Further, we have found that telmisartan, an ARB, downregulates RAGE expression and suppresses its downstream signalings in various cell types through its unique PPARγ-modulating ability.[@R104]--[@R109] Indeed, telmisartan was found to reduce RAGE mRNA levels and subsequently inhibit superoxide generation as well as MCP-1 expression in mesangial cells, all of which were prevented by GW9662, an inhibitor of PPARγ.[@R106] In addition, we have recently found that nifedipine, but not amlodipine, a control calcium channel blocker, decreased RAGE mRNA levels and subsequently reduced ROS generation, and vascular cell adhesion molecule- 1 (VCAM-1) and MCP-1 expression in AGE-exposed mesangial cells, all of which were blocked by the simultaneous treatment of GW9662.[@R111] Although nifedipine did not affect expression levels of PPARγ, it increased the PPARγ transcriptional activity in mesangial cells. Taken together, these observations provide unique beneficial aspect of telmisartsan and nifedipine on diabetic nephropathy; it could work as an anti-inflammatory agent against AGEs by suppressing RAGE expression in cultured mesangial cells via PPARγ activation.

Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors with complex neurotrophic, neuroprotective, anti-angiogenic, anti-oxidative and anti-inflammatory properties, any of which could potentially be exploited as a therapeutic option for the treatment of vascular complications in diabetes.[@R12]--[@R119] There are a couple of papers to suggest the protective effects of PEDF against diabetic nephropathy.[@R120],[@R121] PEDF was decreased at both the mRNA and protein levels in the kidney of diabetic rats, whereas TGFβ and fibronectin levels were increased in the same diabetic kidneys.[@R120] In vitro-studies showed that high concentrations of glucose significantly decreased PEDF secretion in primary human glomerular mesangial cells, thus suggesting that hyperglycemia is a direct cause of the PEDF decrease in the kidney. Further, PEDF blocked the high-glucose-induced overexpression of TGFβ, a major pathogenic factor in diabetic nephropathy, and fibronectin in primary cultured mesangial cells.[@R120] Therefore, decreased expression of PEDF in diabetic kidneys could contribute to extracellular matrix overproduction and the development of diabetic nephropathy. In vivo, overexpression of PEDF was found to alleviate microalbuminuria, to prevent the expression of two major fibrogenic factors, TGFβ and CTGF, and to significantly reduce the production of an extracellular matrix protein in the diabetic kidney.[@R121] Moreover, PEDF upregulated metalloproteinase-2 expression in diabetic kidney, which is responsible for extracellular matrix degradation. Taken together, these findings suggest that PEDF functions as an endogenous anti-TGFβ and anti-fibrogenic factor in the kidney. A therapeutic potential of PEDF in diabetic nephropathy is supported by its downregulation in diabetes, its prevention of the overexpression of TGFβ, CTGF and extracellular matrix proteins accumulation in diabetic kidney and its amelioration of albuminuria. Since we have recently found that PEDF inhibits the AGE-induced vascular permeability by blocking the ROS-mediated VEGF expression,[@R114],[@R115] the salutary effects of PEDF on proteinuria may be ascribed partly to its inhibitory actions on the AGE-signaling to VEGF expression in diabetic nephropathy.

Conclusion
==========

In this paper, we review the pathophysiological role of AGE-RAGE-oxidative stress in diabetic nephropathy. Inhibition of the AGE formation and/or the blockade of RAGE-downstream pathways will be a promising therapeutic strategy for the treatment of diabetic patients with nephropathy.
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###### 

Downstream pathways of the AGE-RAGE axis in diabetic nephropathy

  Intracellular signals                            Target genes                                      Pathology
  ------------------------------------------------ ------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  ROS, NADPH oxidase activation, NFκB, PKC, MAPK   TGFβ, CTGF, Ang II, ICAM-1, VCAM-1, VEGF, MCP-1   inflammation, glomerulosclerosis, tubulointerstitial fibrosis, epithelial-to-mesenchymal transdifferentiation

###### 

Clinical trials of the RAS inhibitors in diabetic nephropathy

  Agents                                                Subjects                                                                                  Clinical outcomes
  ----------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Captopril vs. placebo (ref. [@R84])                   Type 1 diabetic patients with proteinuria more than 500 mg/day                            Captopril treatment was associated with a 50 percent reduction in the risk of the combined end points of death, dialysis, and transplantation.
  Enalapril vs. placebo (ref. [@R85])                   Normotensive, type II diabetic patients with microalbuminuria and normal renal function   Enalapril treatment resulted in long-term stabilization of plasma creatinine levels and of the degree of urinary loss of albumin.
  Irbesartan vs. placebo (ref. [@R86])                  Hypertensive patients with type 2 diabetes and microalbuminuria                           5.2% in the 300-mg group and 9.7% in the 150-mg group reached the primary end point (the time to the onset of diabetic nephropathy), as compared with 14.9% in the placebo group; hazard ratios were 0.30 and 0.61 for the two irbesartan groups, respectively.
  Irbesartan vs. amlodipine vs. placebo (ref. [@R87])   Hypertensive patients with nephropathy due to type 2 diabetes                             Irbesartan treatment was associated with a risk of the primary composite end point (a doubling of the base-line serum creatinine concentration, the development of end-stage renal disease, or death from any cause) that was 20% lower than that in the placebo group and 23% lower than that in the amlodipine group.
  Losartan vs. placebo (ref. [@R88])                    Type 2 diabetic patients with nephropathy                                                 Losartan treatment significantly reduced the risk of the primary outcome (the composite of a doubling of the base-line serum creatinine concentration, end-stage renal disease, or death).
